이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Public Support for COVID-19 Test Allocation

2022년 1월 7일 업데이트: Alison Buttenheim, University of Pennsylvania

Race, Status, Vaccines, Tests, and Place: Public Attitudes and Support for Equitable COVID-19 Vaccine and Test Allocation

In a randomized survey experiment, investigators will assess public support or opposition towards one of three potential government plans for allocating at-home coronavirus disease 2019 (COVID-19) tests to United States residents: 1) first come, first served; 2) a random draw; or 3) a random draw with 20% of tests reserved for disadvantaged areas. Investigators will also examine public attitudes surrounding other logistical and equity-related aspects of these allocation plans.

연구 개요

상세 설명

Complementing other efforts to increase access to COVID-19 testing in the United States, the federal government recently announced the purchase of 500,000,000 at home COVID-19 to be distributed for free "to Americans that want them". A central logistical element in matching supply with demand will be a website, on which people will register their interest in getting tests delivered to their home address. However, it is still unclear how supply will be matched with demand. Three main candidate options are first come, first served (FCFS), in which people are sent tests in the order in which they make requests; a random draw, such as a lottery; or a combination of a random draw with a guaranteed reserved amount for more disadvantaged populations. FCFS is a widely known and practiced rationing principle, but it has shown to exacerbate inequities in, for example, the allocation of vaccine appointments. Random draws can mitigate this impact, but, in the present context, might be insufficiently sensitive to the fact that not everyone has internet access, and that the need for testing is greater among more disadvantaged communities. Combining a lottery with a disadvantage reserve system using measures such as the CDC's Social Vulnerability Index is a practical way of promoting equity, and it was already used by the majority of US states in allocating vaccines. The main objective of this study is to assess public support for each of these three allocation plans and describe differences by demographic characteristics. Investigators will also assess public attitudes toward specific details of these allocation plans. The study, which is expected to take approximately 5 minutes to complete, will be administered as part of an omnibus online survey.

연구 유형

중재적

등록 (실제)

2019

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • District of Columbia
      • Washington, District of Columbia, 미국, 20006
        • Harris Insights & Analytics

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Aged 18 years old or older, United States resident

Exclusion Criteria:

  • None

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 건강 서비스 연구
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: First Come, First Served

Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:"

Below this statement, respondents will view the "First Come, First Served" plan description.

Respondents will view the following description of the plan: "Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'"
실험적: Random

Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:"

Below this statement, respondents will view the "Random" plan description.

Respondents will view the following description of the plan: "People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
실험적: Disadvantaged Priority & Random

Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:"

Below this statement, respondents will view the "Disadvantaged Priority & Random" plan description.

Respondents will view the following description of the plan: "Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them."

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Support for allocation plan
기간: 5 minutes
Self-reported degree of support for the plan, measured on a 5-point Likert scale ("strongly oppose" to "strongly support") that will be collapsed into 3 response categories ("oppose," "neutral," and "support") for analysis.
5 minutes

2차 결과 측정

결과 측정
측정값 설명
기간
Household-level test allocation preference
기간: 5 minutes
Preferred way of sending tests to households, measured as a binary choice between a fixed or variable (based on household size) number of tests per household.
5 minutes
Tests allocated to disadvantaged areas
기간: 5 minutes
Self-reported percentage of tests wanted to be sent to disadvantaged areas, measured as a continuous variable on a slider from 0% to 100% with increments of 0.1%. This outcome will only be measured for respondents in the "Disadvantaged Priority & Random" condition.
5 minutes

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Alison M Buttenheim, PhD, MBA, University of Pennsylvania

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 1월 4일

기본 완료 (실제)

2022년 1월 6일

연구 완료 (실제)

2022년 1월 6일

연구 등록 날짜

최초 제출

2022년 1월 7일

QC 기준을 충족하는 최초 제출

2022년 1월 7일

처음 게시됨 (실제)

2022년 1월 11일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2022년 1월 11일

QC 기준을 충족하는 마지막 업데이트 제출

2022년 1월 7일

마지막으로 확인됨

2022년 1월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

Only de-identified individual participant data will be shared by Harris Insights & Analytics to the research team. Each participant will have a unique identifier to protect their confidentiality. Only authorized research personnel will have access to the data which will be maintained on encrypted hard-drives. Individual participant data may be made available to other researchers in an open-access repository.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다